Viking Global Investors
EIDX

Viking Global Investors’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Viking Global Investors’s Portfolio EIDX Stock Details EIDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-882,353
Closed -$27.4M – 73
2019
Q2 		$27.4M Sell
882,353
-1,103,848
-56% -$29.9M 0.12% 57
2019
Q1 		$46.6M Hold
1,986,201
– – 0.27% 51
2018
Q4 		$27.3M Hold
1,986,201
– – 0.16% 52
2018
Q3 		$19.8M Hold
1,986,201
– – 0.11% 59
2018
Q2 		$40.4M Buy
+1,986,201
New +$41.6M 0.23% 52

Other funds holding EIDX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Viking Global Investors's EIDX Position: Q3 2019 in Review

Viking Global Investors sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q3 2019, closing a stake of 882,353 shares — an estimated $27.4M sold.

Viking Global Investors first reported a position in EIDX in Q2 2018 and held it in 5 quarters. The position peaked at $46.6M in Q1 2019. 79 funds tracked by Wall St. Rank hold EIDX as of Q3 2019.

  • Viking Global Investors reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • Viking Global Investors sold 882,353 Eidos Therapeutics, Inc. Common Stock shares in Q3 2019, an estimated $27.4M.
  • Viking Global Investors first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 5 quarters.
  • Viking Global Investors's Eidos Therapeutics, Inc. Common Stock position peaked at $46.6M in Q1 2019.
  • 79 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Viking Global Investors's 13F filing for Q3 2019, filed 13 Nov 2019.